Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).
暂无分享,去创建一个
F. Saad | N. Shore | C. Pieczonka | P. Sieber | H. Faessel | D. Saltzstein | J. Bailen | D. MacLean | Hongliang Shi